CBD Life Sciences Inc. (CBDL)
OTCMKTS
· Delayed Price · Currency is USD
0.0005
+0.0001 (25.00%)
Dec 24, 2024, 3:00 PM EST
CBD Life Sciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Revenue | 0.18 | 0.17 | 0.16 | 0.08 | 0.23 | 0.08 | Upgrade
|
| Revenue Growth (YoY) | 29.13% | 4.31% | 92.17% | -63.09% | 183.67% | -84.92% | Upgrade
|
| Cost of Revenue | 0.1 | 0.09 | 0.07 | 0.06 | 0.11 | 0.04 | Upgrade
|
| Gross Profit | 0.08 | 0.08 | 0.09 | 0.03 | 0.12 | 0.04 | Upgrade
|
| Selling, General & Admin | 0.13 | 0.1 | 0.89 | 6.15 | 0.5 | 0.45 | Upgrade
|
| Other Operating Expenses | 0 | 0 | 0 | 0.02 | - | - | Upgrade
|
| Operating Expenses | 0.19 | 0.16 | 0.95 | 6.17 | 0.5 | 0.45 | Upgrade
|
| Operating Income | -0.11 | -0.08 | -0.86 | -6.14 | -0.38 | -0.41 | Upgrade
|
| Interest Expense | - | - | - | - | -0.07 | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | - | -0.26 | Upgrade
|
| EBT Excluding Unusual Items | -0.11 | -0.08 | -0.86 | -6.14 | -0.45 | -0.67 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -1.24 | - | Upgrade
|
| Other Unusual Items | - | - | - | - | - | -0.19 | Upgrade
|
| Pretax Income | -0.11 | -0.08 | -0.86 | -6.14 | -1.69 | -0.86 | Upgrade
|
| Net Income | -0.11 | -0.08 | -0.86 | -6.14 | -1.69 | -0.86 | Upgrade
|
| Net Income to Common | -0.11 | -0.08 | -0.86 | -6.14 | -1.69 | -0.86 | Upgrade
|
| Shares Outstanding (Basic) | 136 | 136 | 136 | 78 | 3 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 136 | 136 | 136 | 78 | 3 | 1 | Upgrade
|
| Shares Change (YoY) | 8.24% | - | 73.93% | 2403.73% | 125.06% | - | Upgrade
|
| EPS (Basic) | -0.00 | -0.00 | -0.01 | -0.08 | -0.54 | -0.62 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.00 | -0.01 | -0.08 | -0.54 | -0.62 | Upgrade
|
| Free Cash Flow | -0.02 | -0.02 | -0.87 | -6.44 | -0.66 | -0.77 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.08 | -0.21 | -0.56 | Upgrade
|
| Gross Margin | 45.06% | 47.70% | 53.48% | 32.90% | 53.24% | 46.00% | Upgrade
|
| Operating Margin | -60.21% | -47.01% | -536.57% | -7364.79% | -170.03% | -517.78% | Upgrade
|
| Profit Margin | -60.21% | -47.01% | -536.57% | -7364.79% | -750.07% | -1081.21% | Upgrade
|
| Free Cash Flow Margin | -10.98% | -9.95% | -544.92% | -7728.80% | -292.48% | -965.75% | Upgrade
|
| EBITDA | -0.05 | -0.02 | -0.81 | - | - | -0.34 | Upgrade
|
| EBITDA Margin | -29.07% | -13.77% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.06 | 0.06 | 0.05 | - | - | 0.08 | Upgrade
|
| EBIT | -0.11 | -0.08 | -0.86 | -6.14 | -0.38 | -0.41 | Upgrade
|
| EBIT Margin | -60.21% | -47.01% | - | - | -170.03% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.